Sanofi Reports long-term follow-up Data for Pirtobrutinib in Non-small cell lung cancer

Sanofi today announced long-term follow-up results for pirtobrutinib in patients with non-small cell lung cancer. The study demonstrated that pirtobrutinib demonstrates sustained efficacy compared to standard of care or placebo. These results provide important insights into the treatment of non-small cell lung cancer and support the continued development of pirtobrutinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.